A reported offer for the established MC4R franchise and fresh funding for Lilly-backed Superluminal point to growing interest in the brain’s hunger pathway. Palatin is engineering several ways to compete in its next generation.
After decades with no FDA-approved therapy, Amgen and Novartis both have Phase 3 winners in Sjögren's disease. The harder question is whether either can beat the symptom patients feel most: dryness.
The agency combed trials, real-world claims data, and case reports for two years before putting NAION on every GLP-1 label. The absolute risk is tiny, the relative signal is real, and the decision says a lot about how FDA weighs incomplete evidence.